1.
|
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 15 and over
Sponsor: Other
Protocol IDs: LAL-RI/96, NCT00494897
|
|
2.
|
Phase: Phase IV
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P04594, NCT00687011
|
|
3.
|
Phase: Phase III, Phase II
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: URCC-U1902, URCC-0114, NCI-5857, NCI-P02-0223, NCT00040742
|
|
4.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 25 to 65
Sponsor:
Protocol IDs: DFCI-75116
|
|
5.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 20 and over
Sponsor:
Protocol IDs: SAFR-CT-MM-2
|
|
6.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: under 20
Sponsor:
Protocol IDs: ARG-GATLA-3LMA83
|
|
7.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: under 20
Sponsor:
Protocol IDs: ARG-GATLA-1LLAREC90, NCI-F92-0006, NCT00002499
|
|
8.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: GMALL06, NCT00199108
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 70 and under
Sponsor: NCI
Protocol IDs: SWOG-9321, CLB-9312, E-S9321, INT-0141, NCT00002548
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: at least 1 + under 20 at diag.
Sponsor: NCI
Protocol IDs: CCG-1941
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: any age
Sponsor: Pharmaceutical / Industry
Protocol IDs: MSKCC-94129, NCI-V95-0661
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: CAN-NCIC-MY7, NCI-V95-0713, NCT00002678, MY7
|
|
13.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 15 to 60
Sponsor: Other
Protocol IDs: EORTC-06951, FRE-LALA-94, NCT00002700
|
|
14.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CALGB-9481, ECOG-C9481, NCT00002716
|
|
15.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 1 to 9
Sponsor: NCI
Protocol IDs: CCG-1952, NCT00002744
|
|
16.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: under 15 at initial diagnosis
Sponsor:
Protocol IDs: MRC-LEUK-UKALL-R2, EU-95039
|
|
17.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: over 1 and under 15
Sponsor:
Protocol IDs: MRC-LEUK-UKALL-XI, EU-95036
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: Under 22
Sponsor: NCI
Protocol IDs: COG-2961, CCG-2961, NCT00002798
|
|
19.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 1 to 21
Sponsor: NCI
Protocol IDs: CCG-1961, NCT00002812
|
|
20.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: under 21
Sponsor: NCI
Protocol IDs: CCG-1951, NCT00002816
|
|
21.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: E-1A95, CAN-NCIC-MY8, CLB-E1A95, EORTC-E1A95/06971, SWOG-E1A95, CAN-NCIC-J1A95, CLB-9596, SWOG-S1A95, NCT00002878, E1A95, MY8
|
|
22.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 3 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: DTC-92-001, NCI-V97-1338
|
|
23.
|
Phase: Phase III
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: SWS-SAKK-90/95, EU-97035, NCT00003213
|
|
24.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 21 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BOSTON-VAMC-523, ALZA-97-047-ii, NCI-V98-1422
|
|
25.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: Under 15
Sponsor:
Protocol IDs: UKCCSG-NHL-9503, EU-98012, NCT00003423
|
